Market News AIOpen the app

Traws Pharma shared its financial results for the last quarter and noted progress in its antiviral programs.

ResultsRead the original at SEC EDGAR
Good for TRAW

Traws reported similar symptom relief with fewer treatment-related problems and no viral rebound through Day 28, plus completed TXM testing. FDA discussions and a planned resubmission remain ahead, but the results support the company's outlook.

TRAW · Traws Pharma, Inc.

AI read · Good for TRAW

The AI's read

These findings strengthen the case for ratutrelvir as an option, especially for people unable to take PAXLOVID. The study also found fewer treatment-related problems and no viral rebound through Day 28. Traws also completed a tablet study and toxicology retesting for TXM, supporting a planned resubmission in Q4 2026. FDA discussions and further regulatory steps remain, so neither program's future use is assured.

Get alerts for TRAW

Follow Traws Pharma, Inc. (TRAW) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TRAW
Free on the App Store and Google Play, or on the web.